AbbVie (NYSE:ABBV) and Haisco Pharmaceutical Group announced on April 10, 2026, a strategic licensing agreement to develop and commercialize a portfolio of novel pain compounds.
The deal provides AbbVie with exclusive global rights (excluding Greater China) to a promising pipeline of non-opioid therapies, reinforcing its leadership in the neuroscience and specialty medicine sectors.
Under the terms of the agreement, Haisco—a benchmark enterprise in China's innovative pharmaceutical sector—will receive an upfront cash payment of $30 million.
The company is eligible to receive up to $715 million in additional payments tied to the achievement of development, regulatory, and commercial milestones, plus tiered royalties on future net sales.
The collaboration covers multiple compounds currently at various stages of development in China, ranging from preclinical to Phase 1 clinical trials.
By granting AbbVie exclusive rights to develop, manufacture, and commercialize these assets in all territories except mainland China, Hong Kong, and Macau, Haisco leverages AbbVie’s extensive global R&D and commercial infrastructure to accelerate the time-to-market for these innovative therapies.
The deal comes at a pivotal moment for the pain management market, which is increasingly shifting away from traditional opioids in favor of novel mechanisms with lower addiction potential.
AbbVie, which has made significant investments in its North Chicago API manufacturing facilities throughout early 2026, views the Haisco compounds as a key expansion of its "next-generation" medicine initiative.
The integration of these small-molecule and potentially biologic candidates into AbbVie's pipeline follows the company's recent focus on high-growth therapeutic areas including immunology, oncology, and central nervous system (CNS) disorders.
For Haisco, the deal validates its R&D centers in Chengdu, Shanghai, and Silicon Valley, which currently manage more than 50 active programs.